PerkinElmer’s Horizon Discovery CHOSOURCE™ Platform Expanding To Include CHO-K1 ADCC+ Expression Cell Line for Development of Therapeutic Antibodies in Oncology, Infectious Disease and Autoimmune Conditions

Existing CHO platform, featuring low cost and no royalty or license tie-ins, expands with new cell line to help develop biotherapeutics with increased potency and longevity and  decreased side effects WALTHAM, Mass.– October 6, 2021, PerkinElmer Inc ., a global leader committed to innovating for a


Get every new post delivered right to your inbox.

Original Source